

1 St-Amant et al.

2
3
4 **Prevalence and determinants of cannabinoid prescription for the management of**
5 **chronic non-cancer pain: A postal survey of physicians**
6
7

8
9 Huguette St-Amant, BSc, RN ¹

10 Mark A. Ware, MD, MSc ²

11 Nancy Julien, PhD ¹

12 Anaïs Lacasse, PhD ¹

13
14
15
16
17
18 ¹ Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue,
19 Rouyn-Noranda, Québec, Canada

20
21 ² The Alan Edwards Pain Management Unit, McGill University Health Centre,
22 Montreal, Québec, Canada
23
24
25
26
27
28

29 **Support:** This study was funded by the Fonds institutionnel de la recherche et de la
30 création (FIRC) of Université du Québec en Abitibi-Témiscamingue. We certify that there
31 is no conflict of interest with any funding organization regarding the material discussed in
32 the manuscript.
33
34
35
36
37

38 **Correspondance:**

39 Anaïs Lacasse, PhD

40 Département des sciences de la santé

41 Université du Québec en Abitibi-Témiscamingue

42 445, boul. de l'Université

43 Rouyn-Noranda (Qc), J9X 5E4

44 Phone : (819) 762-0971, 2722

45 E-mail : lacassea@uqat.ca
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 St-Amant et al.
2
3

4 **ABSTRACT**
5
6

7 **Objectives:** Cannabinoid prescription patterns for the management of chronic non-cancer
8 pain (CNCP) are inadequately studied in Quebec as well as in the rest of Canada and
9 internationally. The objectives of this study were to measure the prevalence and identify the
10 determinants of cannabinoid prescription in the management of CNCP.
11
12

13
14 **Methods:** In February 2013, a postal survey was sent out to all physicians of the Abitibi-
15 Témiscamingue region (Quebec) using a modified Dillman method. Multivariate logistic
16 regression models were used to identify determinants of cannabinoids prescription.
17
18

19
20 **Results:** The response proportion was 52.2%, for a total of 166 physicians. A majority of
21 physicians (79.2%) had not attended continuing medical education (CME) activities
22 concerning cannabinoids in the past year. The prevalence of cannabinoid prescription for
23 the management of CNCP was 23.0%, with 91.1% of these physicians prescribing
24 cannabinoids to ≤ 5 patients. Among prescribers, 92.1% reported having prescribed
25 nabilone, 18.4% medical marijuana, and 5.3% nabiximols. Multivariate modelling showed
26 that physicians' comfort level with cannabinoid prescribing was the principal determinant
27 of increased likelihood of cannabinoid prescription. Prescribers and non-prescribers
28 reported that CME activities could increase their comfort level with cannabinoid
29 prescribing. According to physicians, more studies are needed about the efficacy and safety
30 of cannabinoids for the treatment of CNCP.
31
32
33
34
35

36 **Conclusions:** Although cannabinoids are not products of first line in the therapeutic arsenal
37 for the treatment of CNCP, they appear to have their place in the toolbox of physicians.
38 Researchers and educators must work with physicians for optimal and informed
39 cannabinoid prescription and use.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 St-Amant et al.
2
3

4 INTRODUCTION 5

6
7 Between 11 to 29% of the Canadian population is affected by chronic pain (1-4) which is
8 known to have serious consequences for the physical functioning, mental health and quality
9 of life of those who suffer from it (3, 5-7). This health issue also represents a significant
10 economic burden on the healthcare system (8, 9). To date, the treatment of chronic non-
11 cancer pain (CNCP) remains suboptimal, mainly because of a lack of recognition of the
12 condition, not enough training for healthcare professionals, the absence of effective
13 treatment, the lack of access to pain treatment centers and the suboptimal usage of certain
14 drug classes (5, 8, 10-13).
15
16
17
18
19
20
21
22
23
24
25
26
27

28 Cannabinoids are a therapeutic modality for the management of CNCP that has been found
29 effective and safe for some pain syndromes (14-17) while for others, it raises concerns (18,
30 19). A number of pharmaceutical products are available in Canada such as nabilone
31 (Césamet[®]), nabiximols (Sativex[®]) and medical marijuana. However, the usage prevalence
32 of these products for the management of pain symptoms remains low (12-15%) (20-23).
33 This limited use among patients could be partly explained by the stigma associated with
34 smoking marijuana which also affects the products offered in pills or vaporizer (21, 24).
35 Using cannabis for medical purposes is one of the treatments for which users are the most
36 stigmatized regardless of their specific health condition (25). Moreover, the situation could
37 be explained by physicians' lack of comfort regarding these therapeutic modalities (26). As
38 of now, very few studies have been conducted to explore physicians' prescription practices
39 and attitudes toward the use of cannabinoids for the treatment of CNCP in Canada (27).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 St-Amant et al.

2
3
4 It is important to better understand the cannabinoid prescription habits of physicians to
5
6 inform educational programs. The specific objectives of this study were to measure the
7
8 prevalence of cannabinoid prescription for the management of CNCP and identify the
9
10 determinants of cannabinoid prescription. Physicians' comfort level with cannabinoid
11
12 prescribing was also investigated. Considering the attention given to medical cannabis in
13
14 recent medical literature and the new Canadian medical marijuana regulations (28), this is
15
16 an important and timely topic.
17
18
19

20 21 22 23 **METHODS**

24 **Study population**

25
26 The present study was conducted among a convenience sample composed of the physicians
27
28 who are members of the *Collège des Médecins du Québec* (CMQ) and who are practicing
29
30 in one of the five main Health and Social Services Centres (HSSC) of the Abitibi-
31
32 Témiscamingue region of Quebec (Canada). As of January 2013, 318 physicians (family
33
34 physicians: n = 183, physicians practicing another medical speciality: n = 135) met these
35
36 criteria.
37
38
39
40
41
42
43
44

45 **Research design & Protocol**

46
47 In February 2013, a cross-sectional postal survey was sent to all these physicians. The
48
49 protocol was approved by the human research ethics committee of the Université du
50
51 Québec en Abitibi-Témiscamingue.
52
53
54
55

56
57 Participants completed a French language paper-and-pencil self-administered
58
59 questionnaires that they received by mail. A modified Dillman's Total Design Survey
60

1 St-Amant et al.

2
3
4 Method (29) which implies four rounds of postal mail-outs was used. In the first round, an
5
6 introductory letter, the questionnaire and a pre-paid return envelop were mailed to
7
8 participants. The second round involved a reminder postcard sent one week after round one.
9
10 For round three, three weeks after the initial mail-out, a duplicate questionnaire as well as a
11
12 pre-paid return envelop were mailed to the participants who still had not returned their
13
14 questionnaire. Finally, in round four, duplicate questionnaires with a pre-paid return
15
16 envelop were again mailed out, this time seven weeks after round one. Registered mail was
17
18 not used for this seven-week packet contrary to what is suggested by Dillman.
19
20
21

22
23
24 According to recommendations (30-32), some additional strategies were used in order to
25
26 further increase the response proportion. For instance, the cover letter had a blue
27
28 handwritten signature and a direct telephone contact for the principal investigator,
29
30 assurance of confidentiality was given, the correspondence was personalized, the
31
32 questionnaire consisted of 12 pages colour printed pages, and finally a teaser sentence "*By*
33
34 *opening this envelope, you will contribute to research conducted in Abitibi-Témiscamingue*
35
36 *by researchers from here!*" was printed on the mailing envelope. No financial incentives
37
38 were offered to physicians in exchange for their participation.
39
40
41
42
43
44
45

46
47 The first round resulted in a 15.7% response proportion (50 questionnaires), second round
48
49 increased the response proportion to 31.1% (49 questionnaires), round three further
50
51 increased the response proportion to 43.3% (42 questionnaires), and finally round four led
52
53 to a final response proportion of 52.2% (25 questionnaires). Comparison between the
54
55 characteristics of the physicians who participated in the study with those of the physicians
56
57
58
59
60

1 St-Amant et al.

2
3
4 who did not participate was possible since information such as such as medical speciality
5
6 and belonging Health and Social Services Center are published in CMQ's directory.
7
8
9

10 11 **Measures**

12
13
14 The questionnaire was designed to measure cannabinoid prescription patterns of physicians
15
16 specifically regarding CNCP (Appendix I). Measures included the past-year prevalence of
17
18 cannabinoid prescription, types of cannabinoids prescribed, prescription indications,
19
20 physicians' comfort level with cannabinoid prescribing (0 to 10 scale where 0 indicates
21
22 absolutely not comfortable and 10 indicates completely comfortable), characteristics of
23
24 physicians' medical practice, and factors that could increase physicians' comfort level with
25
26 cannabinoid prescribing. Listed factors (list of answer choices) were chosen according to
27
28 previous literature (27) with the option to specify other factors that could increase comfort
29
30 level.
31
32
33
34
35
36
37

38 **Data Analysis**

39
40 Descriptive statistics were conducted in order to describe the sample as well as the study
41
42 variables. Multivariate logistic regression models were used to identify the determinants of
43
44 cannabinoid prescribing for the management of CNCP (yes/no). The choice of variables to
45
46 be included in the final multivariate model was based on their association with this
47
48 dependant variable (all predictors with a p-value ≤ 0.15 in the univariate logistic regression
49
50 models in addition to the number of years of practice). Because of our substantial sample
51
52 size (n = 166), we are confident that the statistical power of the multivariate models was
53
54 sufficient based on the following rule of thumb: sample size $\div 20 =$ the number of variables
55
56
57
58
59
60

1 St-Amant et al.

2
3
4 that can be included in the multivariate model (33, 34). All statistical analyses were
5
6 conducted with the IBM SPSS Statistics software version 19[®].
7
8
9

10 11 **RESULTS**

12 13 14 15 **Prescription habits**

16
17
18 Table 1 shows the socio-demographic characteristics of the 166 physicians who completed
19
20 the questionnaire as well as those of the 152 physicians who failed to return their
21
22 questionnaire. The only difference between the two groups was regarding the HSSC where
23
24 they were practicing. Specifically, physicians from the HSSC Rouyn-Noranda were more
25
26 likely to return their questionnaire than the other physicians. Of the non-responding
27
28 physicians, six called or wrote to the researchers to discuss their reasons for not
29
30 participating: not in a clinical practice (n = 1), doesn't treat chronic pain (n = 1), does not
31
32 prescribe any prescription drugs (n = 3), and cannabinoids are against their values (n = 1).
33
34
35
36
37
38
39

40 Table 2 shows the characteristics of the participating physicians (family physicians: 56%).
41
42 A majority of physicians (79.2%) had not attended any continuing medical education
43
44 (CME) activities about cannabinoids in the past year. The overall prevalence of past-year
45
46 cannabinoid prescription for all potential indications was of 27.3%. As shown in Figure 1,
47
48 the prevalence of cannabinoid prescriptions specifically for the management of CNCP in
49
50 the present sample was 23.0%; 91.1% of these physicians prescribed cannabinoids to ≤ 5
51
52 patients during the past year. Among those who prescribed cannabinoids for the
53
54 management of CNCP, 92.1% prescribed nabilone (Césamet[®]), 18.4 % prescribed medical
55
56 marijuana, and 5.3 % prescribed nabiximols (Sativex[®]).
57
58
59
60

1 St-Amant et al.

2
3
4 When prescription prevalence was stratified by medical speciality, it was found that 34.8%
5
6 of family physicians vs. 8.2% specialists had prescribed cannabinoid for the management of
7
8 CNCP in the past year ($p < 0.05$).
9
10

11 12 13 **Comfort with cannabinoid prescriptions**

14
15
16 Figure 2 shows the degree of comfort with prescribing cannabinoids that physicians have
17
18 reported. A minority of physicians reported a comfort level superior or equal to 6 on a 10
19
20 point scale for the prescription of cannabinoids in general (17.3%) or for the management
21
22 of CNCP (19.4%).
23
24

25
26
27
28 When asked what factors could increase their comfort level with prescribing cannabinoids
29
30 for the management of CNCP (according to cannabinoid prescribers and non prescribers), a
31
32 majority of physicians mentioned attending CME activities about cannabinoids (68.4%),
33
34 having guidelines/algorithms including cannabinoids (67.8%), and having more clinical
35
36 data and new studies (50,0%).
37
38
39
40
41

42 **Determinants of cannabinoid prescriptions**

43
44 Table 3 shows the different variables associated with the prescription of cannabinoid for the
45
46 management of CNCP, both in the univariate logistic regression models and in the final
47
48 multivariate model. The univariate regression models, which do not allow for the
49
50 consideration of intercorrelations between independent variables, suggest that medical
51
52 speciality (specialists vs. family physicians OR : 0.17; 95%CI : 0.07-0.43), practicing in a
53
54 hospital environment (OR : 0.35; 95%CI : 0.16-0.75), practicing in a family medicine
55
56 group/family medicine unit (OR : 3.21; 95%CI : 1.48-6.96), higher weekly caseload (OR :

1 St-Amant et al.

2
3
4 1.02; 95%CI : 1.01-1.03), higher perception of CNCP prevalence in their clientele (OR :
5
6 1.03; 95%CI : 1.01-1.05), and higher degree of comfort with prescribing cannabinoids for
7
8 the management of CNCP (OR : 2.04; 95%CI : 1.64-2.54) were all associated with the
9
10 prescribing of cannabinoids for the management of CNCP ($p < 0.05$). However, when the
11
12 intercorrelations between independent variables were considered (final multivariate model)
13
14 a higher degree of comfort with prescribing cannabinoids for the management of CNCP
15
16 (OR : 1.25; 95%CI : 1.01-1.55) was the only variable that significantly predicts the past-
17
18 year prescription of cannabinoids for the management of CNCP (controlling for the years
19
20 of practice, medical speciality, practicing environment, weekly caseload, perceptions of
21
22 CNCP prevalence in their clientele and the proportion of past-year attended CME about
23
24 cannabinoids).

25
26
27
28
29
30
31
32
33 Figure 3 shows more specifically the correlation between physicians' comfort level with
34
35 prescribing cannabinoids for the management of CNCP and the prevalence of prescription.
36
37 Results indicate that 83% of the variance in prescription prevalence can be explained by
38
39 physician's degree of comfort.
40
41
42
43

44 **INTERPRETATION**

45
46 The present results suggest that the proportion of physicians who have prescribed
47
48 cannabinoid for the management of CNCP is substantial, but this therapeutic modality is
49
50 prescribed to very few patients. Furthermore, the results suggest that the degree of comfort
51
52 with cannabinoids is low and that the more physicians are comfortable with prescribing
53
54 cannabinoid the more likely they are to prescribe cannabinoid products to their patients for
55
56 the management of CNCP.
57
58
59
60

1 St-Amant et al.

2
3
4 The degree of comfort of Canadian physicians regarding cannabinoid prescriptions for the
5 management of CNCP has not been studied. The present results show that they are not
6 comfortable prescribing cannabinoids, as roughly 80% of them reported a degree of
7 comfort below 6 on a 0-10 scale. Furthermore, independent of years of practice, medical
8 speciality, practice environment and the number of CME about cannabinoids attended in
9 the past year, only the degree of comfort with prescribing cannabinoids was found to be a
10 significant determinant of their prescription for the management of CNCP. It is suggested,
11 based on the results of the present study, to target physicians' degree of comfort in the
12 development of new CME activities. Other potential helping factors reported by physicians
13 were the establishment of guidelines/algorithms for cannabinoids prescription. Chronic pain
14 guidelines including these therapeutic agents exist (35, 36) but our findings suggest that
15 these guidelines merit more dissemination. Past research has also found that having a
16 personal positive experience with medical or recreative marijuana could increase
17 physicians' degree of comfort with cannabinoids (37). This was however not assessed in the
18 present study.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Another important result is physicians' low estimation of CNCP prevalence. Specifically,
43 they estimated the prevalence of CNCP in their clientele at 10% or less while it is well
44 accepted that the prevalence of CNCP is around 25% for patients consulting in primary care
45 (38). Furthermore, a high number of the physicians had not attended a training session
46 about CNCP (34%) or about cannabinoids (79.2%) in the past year. Given that the literature
47 suggests that Canadian healthcare professionals manifest a need for better training
48 regarding the treatment of chronic pain (4, 39, 40), it would be beneficial to increase the
49 number of training opportunities.
50
51
52
53
54
55
56
57
58
59
60

1 St-Amant et al.

2
3
4 Finally, although close to a quarter of the physicians (23,0%) reported having prescribed
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Finally, although close to a quarter of the physicians (23,0%) reported having prescribed
cannabinoids for CNCP, most of them (91.1%) had only prescribed it to 5 or less patients in
the preceding 12 months which suggests a low usage of these products among CNCP
patients. To date, few studies of this kind have been conducted with samples of physicians.
In the only other Canadian study conducted, the prescription prevalence was of 35% for
family physicians and 33% for physicians with a different medical speciality (27). In the
present study, when the prescription prevalence is stratified by medical speciality, the
results are in line with those reported by Ziemianski et al. (27) for family physicians
(34.8%) but significantly less physicians with a different medical speciality prescribed
cannabinoids in our sample (8.2%). This difference could be explained by the fact that the
Ziemianski et al. (27) sample was composed of physicians who participated in CME
activities about cannabinoids. Their sample may have been more representative of
physicians interested by this drug class and not necessarily representative of all physicians.
Nonetheless, increased access to CME activities about cannabinoids could help increase the
comfort of physicians with this drug class for the management of CNCP.

42 **Limitations and Strengths**

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The present study has a number of significant strengths such as the usage of a standardized
data collection method, a high response proportion in the context of a physician survey, the
inclusion of numerous potential confounding variables in the data analyses, and a
satisfactory statistical power due to the sample size. However, a number of limitations must
be mentioned. First, even though the participating and non participating physicians were
similar on a large number of characteristics, more physicians from one HSSC participated
compared with the other 4 HSSC of the administrative region where the study was

1 St-Amant et al.

2
3
4 conducted. Also, it is possible that non responders decided not to complete the
5
6
7 questionnaire because they do not prescribe cannabinoids or are not comfortable with them.
8
9 If that was to be true, the present results may present an over-estimation of cannabinoid
10
11 prescription prevalence. Finally, the present results may not be generalizable to all the
12
13 clinical contexts of Canada. However, it is probable that the training needs identified by the
14
15 physicians of the present study are generalizable to other physicians who are not familiar
16
17
18 with this drug class.
19

20 21 22 23 **Conclusion**

24
25 The results of the present study suggest that cannabinoids are not often prescribed for the
26
27 management of CNCP and that physicians are not comfortable with this drug class. This
28
29 degree of discomfort could be addressed by CME activities. Future research is nonetheless
30
31 needed in order to replicate the present results in different regions and to determine the
32
33 objective impact on prescription of offering more CME activities about cannabinoids.
34
35 Although cannabinoids are not products of first line in the therapeutic arsenal for the
36
37 treatment of CNCP, they have their place in the toolbox of physicians. Researchers and
38
39
40 educators must work with physicians for optimal and informed cannabinoid prescription
41
42
43 and use.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 St-Amant et al.
2
3

4 **ACKNOWLEDGMENTS**
5

6 We would like to thank Geneviève L. Lavigne, Ph.D., who helped with the manuscript and
7 provided critical comments. Special thanks to all participating physicians, to the Canadian
8 Pain Society (CPS) and the Quebec Pain Research Network (QPRN), who awarded
9 master's scholarships to Ms St-Amant, and to the Fonds institutionnel de la recherche et de
10 la création (FIRC) of Université du Québec en Abitibi-Témiscamingue who funded the
11 study.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

1 St-Amant et al.

2
3
4 **REFERENCES**

- 5
6
7 1. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada--
8 prevalence, treatment, impact and the role of opioid analgesia. *Pain Research &*
9 *Management*. 2002;7(4):179-84.
- 10
11 2. Ramage-Morin PL, Gilmour H. Chronic pain at ages 12 to 44. *Health Rep*.
12 2010;21(4):53-61.
- 13
14 3. Reitsma ML, Tranmer JE, Buchanan DM, VanDenKerkhof EG. The epidemiology of
15 chronic pain in Canadian men and women between 1994 and 2007: results from the
16 longitudinal component of the National Population Health Survey. *Pain Research &*
17 *Management*. 2012;17(3):166-72.
- 18
19 4. Boulanger A, Clark AJ, Squire P, Cui E, Horbay GL. Chronic pain in Canada: have we
20 improved our management of chronic noncancer pain? *Pain Research & Management*.
21 2007;12(1):39-47.
- 22
23 5. Ashburn MA, Staats PS. Management of chronic pain. *Lancet*. 1999;353(9167):1865-
24 9.
- 25
26 6. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World
27 Health Organization study in primary care. *JAMA*. 1998;280(2):147-51.
- 28
29 7. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the
30 general population. *Archives of General Psychiatry*. 2003;60(1):39-47.
- 31
32 8. Kronborg C, Handberg G, Axelsen F. Health care costs, work productivity and activity
33 impairment in non-malignant chronic pain patients. *The European journal of health*
34 *economics : HEPAC : health economics in prevention and care*. 2009;10(1):5-13.
- 35
36 9. Guerriere DN, Choiniere M, Dion D, Peng P, Stafford-Coyte E, Zagorski B, et al. The
37 Canadian STOP-PAIN project - Part 2: What is the cost of pain for patients on waitlists
38 of multidisciplinary pain treatment facilities? *Can J Anaesth*. 2010;57(6):549-58.
- 39
40 10. MacDonald NE, Flegel K, Hebert PC, Stanbrook MB. Better management of chronic
41 pain care for all. *CMAJ : Canadian Medical Association journal = journal de*
42 *l'Association medicale canadienne*. 2011;183(16):1815.
- 43
44 11. Sarzi-Puttini P, Vellucci R, Zuccaro SM, Cherubino P, Labianca R, Fornasari D. The
45 appropriate treatment of chronic pain. *Clinical drug investigation*. 2012;32 Suppl 1:21-
46 33.
- 47
48 12. Zuccaro SM, Vellucci R, Sarzi-Puttini P, Cherubino P, Labianca R, Fornasari D.
49 Barriers to pain management : focus on opioid therapy. *Clinical drug investigation*.
50 2012;32 Suppl 1:11-9.
- 51
52
53
54
55
56
57
58
59
60

1 St-Amant et al.

- 2
- 3
- 4
- 5 13. Sessle BJ. The pain crisis: what it is and what can be done. *Pain research and*
- 6 *treatment*. 2012;2012:703947.
- 7
- 8 14. Bonfa L, Vinagre RC, de Figueiredo NV. Cannabinoids in chronic pain and palliative
- 9 *care*. *Revista brasileira de anesthesiologia*. 2008;58(3):267-79.
- 10
- 11 15. Cohen SP. Cannabinoids for chronic pain. *BMJ (Clinical research ed)*.
- 12 *2008;336(7637):167-8*.
- 13
- 14 16. Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. *Journal of*
- 15 *opioid management*. 2009;5(6):341-57.
- 16
- 17
- 18 17. Lynch ME, Campbell F. Cannabinoids for Treatment of Chronic Non-Cancer Pain: A
- 19 *Systematic Review of Randomized Trials*. *British journal of clinical pharmacology*.
- 20 *2011;72(5):735-44*.
- 21
- 22 18. Kahan M, Srivastava A. New medical marijuana regulations: the coming storm. *CMAJ*
- 23 *: Canadian Medical Association journal = journal de l'Association medicale*
- 24 *canadienne*. 2014;186(12):895-6.
- 25
- 26
- 27 19. Fitzcharles MA, Clauw DJ, Ste-Marie PA, Shir Y. The dilemma of medical marijuana
- 28 *use by rheumatology patients*. *Arthritis care & research*. 2014;66(6):797-801.
- 29
- 30 20. Choinière M, Dion D, Peng P, Banner R, Barton PM, Boulanger A, et al. The Canadian
- 31 *STOP-PAIN project - Part 1: Who are the patients on the waitlists of multidisciplinary*
- 32 *pain treatment facilities? Canadian journal of anaesthesia = Journal canadien*
- 33 *d'anesthesie*. 2010;57(6):539-48.
- 34
- 35
- 36 21. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among
- 37 *patients with multiple sclerosis*. *Neurology*. 2004;62(11):2098-100.
- 38
- 39 22. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-
- 40 *cancer pain: results of a prospective survey*. *Pain*. 2003;102(1-2):211-6.
- 41
- 42 23. Ste-Marie PA, Fitzcharles M-A. Cannabinoid use in fibromyalgia is associated with
- 43 *male gender, opioid use and drug seeking behaviour*. *Pain Research & Management*.
- 44 *2012;17(3):224*.
- 45
- 46 24. Gill A, Williams ACdC. Preliminary study of chronic pain patients' concerns about
- 47 *cannabinoids as analgesics*. *The Clinical journal of pain*. 2001;17(3):245-8.
- 48
- 49 25. Bottorff JL, Bissell LJ, Balneaves LG, Oliffe JL, Capler NR, Buxton J. Perceptions of
- 50 *cannabis as a stigmatized medicine: a qualitative descriptive study*. *Harm reduction*
- 51 *journal*. 2013;10:2.
- 52
- 53 26. Juurlink DN. Medicinal cannabis: Time to lighten up? *CMAJ : Canadian Medical*
- 54 *Association journal = journal de l'Association medicale canadienne*. 2014;186(12):897-
- 55 *8*.
- 56
- 57
- 58
- 59
- 60

1 St-Amant et al.

- 2
- 3
- 4 27. Ziemianski D, Tekanoff R, Luconi F, Ware M. Cannabinoids in clinical practice:
5 experiences and educational needs. *Pain Research & Management*. 2012;17(3):229.
- 6
- 7
- 8 28. Health Canada. *Medical Use of Marijuana*. Ottawa: Government of Canada, 2014.
- 9
- 10 29. Dillman DA. *Mail and telephone surveys*. New-York: Wiley Interscience; 1978.
- 11
- 12 30. Field TS, Cadoret CA, Brown ML, Ford M, Greene SM, Hill D, et al. Surveying
13 physicians: do components of the "Total Design Approach" to optimizing survey
14 response rates apply to physicians? *Med Care*. 2002;40(7):596-605.
- 15
- 16
- 17 31. Thorpe C, Ryan B, McLean SL, Burt A, Stewart M, Brown JB, et al. How to obtain
18 excellent response rates when surveying physicians. *Fam Pract*. 2009;26(1):65-8.
- 19
- 20 32. Hoddinott SN, Bass MJ. The dillman total design survey method. *Canadian family
21 physician Medecin de famille canadien*. 1986;32:2366-8.
- 22
- 23 33. Vittinghoff E, McCulloch CE. Relaxing the Rule of Ten Events per Variable in
24 Logistic and Cox Regression. *Am J Epidemiol*. 2007;165(6):710-8.
- 25
- 26
- 27 34. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in
28 developing models, evaluating assumptions and adequacy, and measuring and reducing
29 errors. *Statistics in medicine*. 1996;15(4):361-87.
- 30
- 31 35. Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. Guidelines for
32 the use of cannabinoid compounds in chronic pain. *Pain research & management : the
33 journal of the Canadian Pain Society = journal de la societe canadienne pour le
34 traitement de la douleur*. 2005;10 Suppl A:44A-6A.
- 35
- 36
- 37 36. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS
38 guidelines on pharmacological treatment of neuropathic pain. *European journal of
39 neurology : the official journal of the European Federation of Neurological Societies*.
40 2006;13(11):1153-69.
- 41
- 42
- 43 37. Kondrad E, Reid A. Colorado family physicians' attitudes toward medical marijuana.
44 *Journal of the American Board of Family Medicine : JABFM*. 2013;26(1):52-60.
- 45
- 46 38. Gureje O, Simon GE, Von Korff M. A cross-national study of the course of persistent
47 pain in primary care. *Pain*. 2001;92(1-2):195-200.
- 48
- 49 39. Bergeron D, Gallagher F, Bourgault P. Analyse des activités en gestion de la douleur
50 chronique réalisées par le personnel infirmier des groupes de médecine de famille
51 (GMF). *Pain Research and Management*. 2011;16(2):102.
- 52
- 53
- 54 40. Leroux-Lapointe V, Choinière M, Dion D, Lamarre D, Thiffault R, Lussier D, et al.
55 The ACCORD program: Knowledge, attitudes and beliefs of community pharmacists
56 about non-cancer chronic pain. *Can J Clin Pharmacol*. 2010;17(1):e-116.
- 57
- 58
- 59
- 60

Table 1. Comparison between the characteristics of the physicians who participated in the study with those of the physicians who did not participate.

Physicians' characteristics	Participants (n=166)	Non participants (n=152)
Medical speciality – n (%)		
Family physician	93 (56.0)	87 (57.2)
Other speciality	73 (44.0)	65 (42.8)
Sexe – n (%)		
Male	77 (46.4)	81 (53.3)
Female	89 (53.6)	71 (46.7)
HSSC – n (%)		
HSSC Rouyn-Noranda	62 (37.3)	34 (22.4)
HSSC Vallée-de-l'Or	46 (27.7)	34 (22.4)
Other HSSC ^a	58 (34.9)	84 (55.3)

HSSC = Health and Social Services Centers

^a HSSC Aurores-Boréales, HSSC Témiscamingue and HSSC Les Eskers de l'Abitibi.

St-Amant et al.

Table 2. Characteristics of participating physicians

Characteristics	n= 166
Socio-demographic characteristics	
Years of practice – n (%)	
0-5	30 (18.5)
6-10	20 (12.3)
11-20	50 (30.9)
21+	62 (38.3)
Sexe – n (%)	
Female	89 (53.6)
Male	77 (46.4)
Medical speciality – n (%)	
Family physician/General partitionner	93 (56.0)
Other medical speciality	73 (44.0)
Type of medical work environment frequented in the past year– n (%) ^a	
Hospital environment (excluding the ER)	87 (53.4)
FMU/FMG	43 (26.4)
ER	35 (21.5)
Private medical office	21 (12.9)
Environment offering palliative care	11 (6.7)
CLSC (Local Community Services Centers)	12 (7.4)
CHSLD (Long-term care facility)	8 (4.9)
ASSSAT (Health and social services agency of the Abitibi-Témiscamingue region)	6 (3.7)
Other	5 (3.1)
Medical practice characteristics	
Proportion of medical practice dedicated to seeing patients in the past year (%)	
Mean ± SD	82.40 ± 24.25
Median	90
Min	0
Max	100
Proportion of medical practice dedicated to seeing patients in the past year– n (%)	
<50 %	13 (8.1)
≥50 %	147 (91.9)
Number of patients seen each week within the medical practice	
Mean ± SD	58.42 ± 37.24
Median	50
Min	0
Max	250

St-Amant et al.

Prevalence of Chronic Non-Cancer Pain in your clientele (%)	
Mean \pm SD	22.06 \pm 17.44
Median	20.0
Min	0
Max	100
Prevalence of Chronic Non-Cancer Pain in your clientele – n (%)	
<50 %	146 (91.8)
\geq 50 %	13 (8.2)
Proportion of the Continuing Medical Education activities about CNCP and its treatment in the past year – n (%)	
0 %	54 (34.0)
1-10 %	71 (44.7)
11-20 %	28 (17.6)
21-30 %	4 (2.5)
31-40 %	2 (1.3)
Proportion of the Continuing Medical Education activities about cannabinoids in the past year– n (%)	
0 %	126 (79.2)
1-10 %	32 (20.1)
11-20 %	1 (0.6)

Proportion of missing data \leq 4.2 %; CNCP = Chronic Non-Cancer Pain, FMG = Family medicine group, FMU = Family medicine unit

^a Categories are not mutually exclusive. A physician could be working in more than one environment.

St-Amant et al.

Table 3. Physicians' characteristics and their medical practice in relation with their prevalence of cannabinoid prescriptions for the management of CNCP.

Predictors	No (n = 127)	Yes (n = 38)	p-value of the univariate logistic regression	Crude OR (95% CI)	Adjusted OR (95% CI) ***
Years of practice – n (%)					
0- 20 years (référence)	92 (62.6)	8 (57.1)		-	-
21 years and more	55 (37.4)	6 (42.9)	0.689	1.255 (0.413 - 3.807)	0.704 (0.174-2.838)
Sexe – n (%)					
Male (référence)	59 (46.5)	18 (47.4)		-	
Female	68 (53.5)	20 (52.6)	0.921	0.964 (0.466-1.993)	
Medical speciality – n (%)					
Family physicians (référence)	60 (47.2)	32 (84.2)		-	-
Other medical speciality	67 (52.8)	6 (15.8)	0.000 *	0.168 (0.066-0.429)	0.140 (0.011- 1.711)
Practice mostly in hospital environment (excluding ER) – n (%)					
No (référence)	50 (40.3)	25 (65.8)		-	-
Yes	74 (59.7)	13 (34.2)	0.007 *	0.351 (0.164-0.751)	1.898 (0.423-8.509)
Practice mostly in the ER – n (%)					
No (référence)	98 (79.0)	29 (76.3)		-	
Yes	26 (21.0)	9 (23.7)	0.722	1.170 (0.493-2.775)	
Practice mostly in a FMG/FMU – n (%)					
No (référence)					
Yes	99 (79.8)	21 (55.3)		-	-
	25 (20.2)	17 (44.7)	0.003 *	3.206 (1.476-6.962)	1.521 (0.395-5.856)
Practice mostly in private medical office – n (%)					
No (référence)	111 (89.5)	30 (78.9)		-	-
Yes	13 (10.5)	8 (21.1)	0.096 **	2.277 (0.864-5.998)	1.330 (0.288-6.154)

St-Amant et al.

Proportion of the medical practice dedicated to seeing patients in the past year (%) – Mean ± SD	80.29 ± 28.35	86.32 ± 14.03	0.215	1.011 (0.994-1.029)	
Number of patients seen in a week in the medical practice– Mean ± SD	52.30 ± 33.09	73.63 ± 47.28	0.005 *	1.015 (1.005-1.025)	1.006 (0.992-1.021)
Perception of CNCP prevalence in their clientele (%) – Mean ± SD	19,73 ± 15,14	28,55 ± 22,21	0,011 *	1,027 (1,006-1,049)	1,010 (0,976-1,044)
Proportion of Continuing Medical Educations activities about CNCP and its treatment in the past year, recoded – n (%)					
0 - 10% (reference)	114 (79,2)	11 (78,6)			
11 - 40%	30 (20,8)	3 (21,4)	0,958	1,036 (0,272-3,952)	
Proportion of Continuing Medical Education activities about cannabinoids in the past year, recoded – n (%)					
0% (reference)	116 (80,6)	10 (71,4)			
1 - 20%	28 (19,4)	4 (28,6)	0.421	1.657 (0.484-5.674)	
Degree of current comfort with prescribing cannabinoids for the management of CNCP – Mean ± SD	1.39 ± 1.85	5.92 ± 2.54	0.000 *	2.039 (1.640-2.535)	1.252 (1.009-1.553)

CNCP = Chronic Non-Cancer Pain, FMG = Family medicine group, FMU = Family medicine unit

* p-value < 0.05

** 0.05 ≤ p-value ≤ 0.15

*** Estimation of the adjusted OR for all predictors with a p-value ≤ 0.15 in the univariate logistic regression models. We also choose to enter the number of years of practice in the multivariate model.

1 St-Amant et al.

2
3
4 **FIGURES**

5
6
7 **Figure 1. Cannabinoid prescription prevalence in the past year for a number of**
8 **therapeutic indications among participating physicians.**

9
10 **Figure 2. Degree of current comfort of participating physicians with the prescription**
11 **of cannabinoids.**

12
13 **Figure 3. Correlation between physicians' degree of comfort in prescribing**
14 **cannabinoids for the management of CNCP and the past-year prevalence of**
15 **cannabinoid prescriptions for the management of CNCP.**
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

St-Amant et al.




Figure 1. Cannabinoid prescription prevalence in the past year for a number of therapeutic indications among participating physicians.

CNCP = Chronic Non-Cancer Pain

Proportion of missing data = 0.6 %.




Figure 2. Degree of current comfort of participating physicians with the prescription of cannabinoids.

CNCP = Chronic Non-Cancer Pain

Proportion of missing data = 6.0-6.6 %.

St-Amant et al.




Figure 3. Correlation between physicians' degree of comfort in prescribing cannabinoids for the management of CNCP and the past-year prevalence of cannabinoid prescriptions for the management of CNCP.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Université du Québec
en Abitibi-Témiscamingue

**La prescription de
cannabinoïdes pour la
prise en charge de la
douleur chronique non
cancéreuse en Abitibi-
Témiscamingue**

Questionnaire adressé aux médecins



Préambule

La douleur chronique, qui a des répercussions importantes sur le fonctionnement physique et psychologique des personnes qui en souffrent, touche environ un adulte sur cinq au Québec. Les syndromes de douleur chronique non cancéreuse comprennent notamment la lombalgie, la cervicalgie, l'arthrite rhumatoïde, l'arthrose, les migraines, les céphalées, la fibromyalgie, le syndrome du côlon irritable, les névralgies ainsi que les douleurs chroniques post-traumatiques ou postchirurgicales.

Parmi les modalités thérapeutiques permettant une prise en charge de la douleur chronique, les cannabinoïdes naturels et synthétiques se sont avérés efficaces et sécuritaires pour certains de ces syndromes. Ces produits pharmacologiques comprennent le nabilone (Césamet[®]), le dronabinol (Marinol[®]), le THC/cannabidiol (Sativex[®]) et la marijuana à des fins médicales. Ceux-ci sont tous disponibles avec ordonnance au Canada.

Les questions suivantes portent sur les tendances de prescription, le degré de confort, les besoins en matière de formation et les barrières face à la prescription de cannabinoïdes. Nous vous invitons à inscrire vos réponses au meilleur de votre connaissance.

Tendances de prescription de cannabinoïdes

1. Au cours de la dernière année, avez-vous prescrit des cannabinoïdes?

₀ Non ₁ Oui

Si oui, lesquels? *(Cochez plusieurs cases, s'il y a lieu)*

- Nabilone (Césamet[®])
- Dronabinol (Marinol[®])
- THC/cannabidiol (Sativex[®])
- Marihuana à des fins médicale (Programme d'accès de Santé Canada)

Si oui, pour quel(s) problème(s) de santé?

(Cochez plusieurs cases, s'il y a lieu)

- Douleur chronique non cancéreuse
- Douleur chronique cancéreuse
- Douleur aiguë
- Anorexie avec perte de poids
- Anxiété
- Nausées et vomissements
- Sommeil
- Spasticité
- Autres (veuillez préciser) : _____

Si oui, à combien de patients (dans la dernière année)?

₀ 1-5 ₁ 6-10 ₂ 11-20 ₃ 21-50 ₄ >50

Si non, pourquoi?

Degré de confort envers la prescription de cannabinoïdes

2. Actuellement, quel est votre degré de confort à prescrire des cannabinoïdes (toutes indications confondues)? *(Veuillez encercler la réponse)*

0 1 2 3 4 5 6 7 8 9 10
Inconfortable Confortable

3. Actuellement, quel est votre degré de confort à prescrire des cannabinoïdes pour la prise en charge de la douleur chronique non cancéreuse? *(Veuillez encercler la réponse)*

0 1 2 3 4 5 6 7 8 9 10
Inconfortable Confortable

4. Quels facteurs pourraient augmenter votre degré de confort à prescrire des cannabinoïdes pour la prise en charge de la douleur chronique non cancéreuse? *(Cochez plusieurs cases, s'il y a lieu)*

- Données cliniques/nouvelles études
- Données sur l'efficacité de ces produits
- Données sur l'innocuité à long terme
- Données sur la dépendance à long terme
- Lignes directrices/algorithmes qui intègrent les cannabinoïdes
- Nouvelles indications thérapeutiques
- Éducation et sensibilisation des patients
- Formation médicale continue
- Discussions entre pairs
- Autres (veuillez préciser) : _____

Besoins en matière de formation face à l'utilisation et à la prescription de cannabinoïdes

5. Pour chacun des thèmes ci-dessous, veuillez entourer le chiffre qui décrit le mieux votre niveau de connaissance actuel et le niveau de connaissance que vous souhaiteriez avoir :

Veuillez encercler le chiffre qui décrit le mieux votre opinion sur une échelle de 0 à 5, où 0 correspond à un niveau de connaissance nul et 5 à un excellent niveau de connaissance.

Niveau de connaissance actuel						Thèmes	Niveau de connaissance souhaité					
Nul	→				Excellent		Nul	→				Excellent
0	1	2	3	4	5	Douleur chronique non cancéreuse et son traitement	0	1	2	3	4	5
0	1	2	3	4	5	Mécanismes d'action des cannabinoïdes (système endocannabinoïde)	0	1	2	3	4	5
0	1	2	3	4	5	Cannabinoïdes disponibles (molécules existantes)	0	1	2	3	4	5
0	1	2	3	4	5	Prescription efficace des cannabinoïdes (toutes indications confondues)	0	1	2	3	4	5
0	1	2	3	4	5	Prescription de cannabinoïdes pour la prise en charge de la douleur chronique non cancéreuse	0	1	2	3	4	5
0	1	2	3	4	5	Risques de l'utilisation des cannabinoïdes à long terme	0	1	2	3	4	5
0	1	2	3	4	5	Lois et réglementation entourant l'utilisation de marijuana à des fins médicales de Santé Canada	0	1	2	3	4	5
0	1	2	3	4	5	Synergie d'action entre les cannabinoïdes et les opioïdes	0	1	2	3	4	5

6. Selon votre expérience, pour quel(s) syndrome(s) de douleur chronique non cancéreuse les cannabinoïdes peuvent-ils être efficaces? *(Cochez plusieurs cases, s'il y a lieu)*

- | | |
|--|---|
| <input type="checkbox"/> Arthrite rhumatoïde | <input type="checkbox"/> Fibromyalgie |
| <input type="checkbox"/> Arthrose | <input type="checkbox"/> Lombalgie |
| <input type="checkbox"/> Céphalées de tension | <input type="checkbox"/> Migraines |
| <input type="checkbox"/> Cervicalgie | <input type="checkbox"/> Syndrome du côlon irritable |
| <input type="checkbox"/> Douleur neuropathique | <input type="checkbox"/> Autres (veuillez préciser) : _____ |

Barrières face à l'utilisation de cannabinoïdes

7. Selon vous, est-ce que les facteurs suivants sont des barrières à l'utilisation des cannabinoïdes pour la prise en charge de la douleur chronique non cancéreuse dans la pratique médicale actuelle?

Veillez encercler le chiffre qui décrit le mieux votre opinion sur une échelle de 0 à 5, où 0 n'est pas une barrière et 5 est une barrière importante.

Barrières potentielles	Votre opinion					
	N'est pas une barrière → Est une barrière importante					
Degré d'efficacité des cannabinoïdes	0	1	2	3	4	5
Risques/Effets indésirables	0	1	2	3	4	5
Données probantes limitées	0	1	2	3	4	5
Fenêtre thérapeutique étroite	0	1	2	3	4	5
Interactions médicamenteuses	0	1	2	3	4	5
Suivi nécessaire/Monitorage	0	1	2	3	4	5
Manque de lignes directrices pour leur utilisation	0	1	2	3	4	5
N'est pas un premier choix de traitement	0	1	2	3	4	5
Les patients ont tendance à sous-rapporter leurs symptômes douloureux	0	1	2	3	4	5
Stigma social associé aux cannabinoïdes (tabous et préjugés)	0	1	2	3	4	5
Craintes des patients/de leur famille	0	1	2	3	4	5
Manque de formation des professionnels de la santé	0	1	2	3	4	5
Considérations légales	0	1	2	3	4	5
Possibilité que le patient utilise les cannabinoïdes dans un but récréatif	0	1	2	3	4	5
Possibilité de vente sur le marché noir	0	1	2	3	4	5
Autres barrières et commentaires :						
<hr/>						
<hr/>						

Caractéristiques de la pratique médicale

8. Êtes-vous un homme ou une femme?

₀ Homme ₁ Femme

9. Depuis combien d'années pratiquez-vous la médecine?

₀ 0-5 ₁ 6-10 ₂ 11-20 ₃ 21+

10. Quelle est votre spécialité médicale?

₀ Médecin de famille/Omnipraticien ₁ Autre spécialité médicale

11. Au cours de la dernière année, dans quel type de milieu de pratique avez-vous passé la majorité de votre temps?

- ₀ Hôpital - Clinique externe
- ₁ Hôpital - Salle d'urgence
- ₂ Groupe de médecine de famille (GMF)
- ₃ Cabinet médical privé
- ₄ Milieux offrant des soins palliatifs
- ₅ CLSC - Centre local de services communautaires
- ₆ CHSLD - Centre d'hébergement et de soins de longue durée
- ₇ Agence de la santé et des services sociaux de l'Abitibi-Témiscamingue (ASSSAT)
- ₈ Autre (veuillez préciser) : _____

12. Au cours de la dernière année, quelle était la proportion de votre pratique médicale consacrée à voir des patients? *(Veuillez encercler la réponse)*

0 % 10 20 30 40 50 60 70 80 90 100 %

13. En moyenne, combien de patients rencontrez-vous par semaine dans le cadre de votre pratique médicale?

patients/semaine

Aucun, car je n'effectue pas le suivi de patients

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

14. Selon vous, quelle est la prévalence (%) de douleur chronique non
cancéreuse au sein de votre clientèle? *(Veuillez encrer la réponse)*

0 % 10 20 30 40 50 60 70 80 90 100 %

Non applicable, car je n'effectue pas le suivi de patients

15. Durant la dernière année, quelle proportion de vos activités de formation
médicale continue portait sur la douleur chronique non cancéreuse et son
traitement?

₀ 0 % ₁ 1-10 % ₂ 11-20 % ₃ 21-30 % ₄ 31-40 % ₅ >40 %

16. Durant la dernière année, quelle proportion de vos activités de formation
médicale continue portait sur les cannabinoïdes?

₀ 0 % ₁ 1-10 % ₂ 11-20 % ₃ 21-30 % ₄ 31-40 % ₅ >40 %

Lorsque l'étude sera terminée, souhaitez-vous recevoir un résumé des
résultats par courrier électronique?

Non

Oui : _____ @ _____

Le questionnaire se termine ici

**Veillez vous assurer d'avoir répondu à toutes les questions et nous
retourner le questionnaire dans l'enveloppe-réponse au cours de la
semaine prochaine afin d'éviter que nous vous relançons inutilement.**

Merci beaucoup de votre participation!